-+ 0.00%
-+ 0.00%
-+ 0.00%

Propanc Biopharma Engages Manufacturer For Its Lead Asset PRP Ahead Of The Upcoming Phase 1b, First-in-Human Study In 30-40 Advanced Cancer Patients Suffering From Solid Tumors

Benzinga·05/19/2026 12:53:18
Listen to the news

Based in Europe, the CDMO provides end-to-end services for preclinical and clinical projects, with extensive experience in decoding biologics production (plasmid DNA and recombinant proteins) providing services of cell line generation, banking and characterization, analytical development, process development and batches production of both drug substances and drug products (decoding biologics production refers to the specialized process of understanding, optimizing, and controlling the manufacturing of complex medicines derived from living cells, such as proteins, vaccines, and monoclonal antibodies).